Acting On Peptide Bonds (3.4) (e.g., Urokinease, Etc.) Patents (Class 424/94.63)
Metalloproteinases (3.4.24) (e.g., collagenase, snake venom zinc proteinase, etc.) (Class 424/94.67)
-
Publication number: 20140314676Abstract: The current application is directed to methods of treating or ameliorating myocardial ischemia, an acute coronary event, and a myocardial reperfusion injury comprising administering a therapeutically effective amount of deferiprone or a pharmaceutically acceptable salt thereof to a patient in need thereof. The application is also directed to reducing the risk for myocardial reperfusion injury as well as promoting the beneficial remodeling of cardiac tissue in a patient, comprising administering a therapeutically effective amount of deferiprone or a pharmaceutically acceptable salt thereof to a patient before, during or after reperfusion therapy. The application also includes methods of selecting a patient for treatment of reperfusion injury and subsequently treating the selected patient.Type: ApplicationFiled: November 16, 2012Publication date: October 23, 2014Inventors: Michael Spino, John Chalmers Connelly, John Charles Wood, Graham Arnold Wright, Nilesh Ramesh Ghugre
-
Publication number: 20140302004Abstract: Multi-drug resistant superbugs are a persistent problem in modern health care. This invention provides an antimicrobial endolysin-Lysostaphin triple fusion protein, comprising (1) an endolysin CHAP endopeptidase domain, (2) an endolysin amidase domain, and (3) a Lysostaphin glycyl-glycine endopeptidase domain. The domains are derived from two proteins that show antimicrobial synergy when used in combination. The protein has specificity and exolytic activity for the peptidoglycan cell wall of untreated, live Staphylococcus aureus from many growth phases i.e. stationary, logarithmic and biofilm growth. The recombinant triple fusion protein comprising the three functional antimicrobial domains is designed to be refractory to resistance development.Type: ApplicationFiled: March 18, 2013Publication date: October 9, 2014Applicant: The United Sates of America, as represented by the Secretary of AgricultureInventor: The United Sates of America, as represented by the Secretary of Agriculture
-
Publication number: 20140286943Abstract: The present invention relates to new cyclopropyl modulators of P2Y12 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: June 9, 2014Publication date: September 25, 2014Inventors: Tadimeti Rao, Chengzhi Zhang
-
Publication number: 20140287035Abstract: Compositions of the present invention, comprising the combination of enterically coated and uncoated pancreatic enzyme-containing beads are useful for treating or preventing pancreatitis pain, and optionally disorders associated with digestive enzyme deficiencies.Type: ApplicationFiled: June 5, 2014Publication date: September 25, 2014Inventors: Stephen Perrett, Ruth Thieroff-Ekerdt, Gopi Venkatesh, Konstantinos Efthymiopoulos
-
Patent number: 8834908Abstract: A pest-combating composition including sodium lauryl sulfate and one or more of C6-12 fatty acids, preferably lauric and/or capric and/or caprylic acid, soy methyl ester, and 2-undecanone, and methods of combating pests utilizing same, are disclosed. The compositions can include a carrier oil such as silicon oil, soy methyl ester, or a vegetable oil, and can be in the form of an emulsion. The composition may be constituted as a spray composition, an aerosol, a lotion, a paste, or another compositional form. Pests that may be usefully combated with such composition include flying insects, including flies, mosquitoes, and wasps, ants, including arthropods such as fire ants, ticks, fleas, cockroaches, silver fish, thrips, gnats, aphids, Japanese beetles, and agricultural and horticultural arthropods and insects including beetles (potato and bean), flea beetles, fleahoppers, squash bugs, slugs, leaf hoppers, harlequin bugs, milk weed bugs, spiders, mites, lice, rodents, and deer.Type: GrantFiled: February 22, 2012Date of Patent: September 16, 2014Assignee: HOMS, LLCInventor: Allen Jones
-
Patent number: 8834869Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.Type: GrantFiled: November 29, 2012Date of Patent: September 16, 2014Assignee: ThromboGenics NVInventors: Steve Pakola, Marc De Smet
-
Publication number: 20140248258Abstract: The present invention provides methods for improving gut health. In particular, the invention provides methods for improving gut health by improving the digestibility of dietary proteins, decreasing the flow of protein to the lower gastrointestinal tract, and/or decreasing the levels of Clostridium bacteria the upper intestinal tract of a subject. The methods comprise administering to the subject a supplement consisting essentially of at least one protease.Type: ApplicationFiled: May 15, 2014Publication date: September 4, 2014Applicant: NOVUS INTERNATIONAL, INC.Inventors: Chris D. Knight, Julia J. Dibner, Fenglan Yan
-
Publication number: 20140242036Abstract: The instant invention refers to a novel process for potentiating the production of substances with antifungal activity obtained from Ganoderma lucidum, using a technological device for the differential, qualitative and quantitative expression of proteins and other bioactive molecules, selected from the group consisting of polysaccharides, triterpenoids, fatty acids and ganoderic acids. The compositions containing said substances showed antifungal activity and mycelium growth and fungi ascospore germination inhibiting activity, amongst them Mycosphaerella fijiensis, primary pathogenic agent causing black Sigatoka disease in banana and plantain crop fields.Type: ApplicationFiled: June 18, 2013Publication date: August 28, 2014Inventors: JOHN JAIRO MIRA CASTILLO, PAOLA ANDREA ZAPATA OCAMPO, LUCíA ATEHORTÚA GARCÉS, LIUDA JOHANA SEPÚLVEDA ARANGO, DIEGO FERNANDO ROJAS VAHOS
-
Patent number: 8802729Abstract: Biodegradable detergent compositions comprising enzymes and 1,3-propanediol are provided. The 1,3-propanediol in the composition is biologically derived and enhances the stability of the enzymes in the composition. The compositions also exhibit a low anthropogenic CO2 emission profile.Type: GrantFiled: March 15, 2013Date of Patent: August 12, 2014Assignee: DuPont Tate & Lyle Bio Products Company, LLCInventors: Gyorgyi Fenyvesi, Melissa Joerger, Robert Miller, Raja Hari Poladi, Ann Wehner
-
Publication number: 20140219989Abstract: The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.Type: ApplicationFiled: July 3, 2012Publication date: August 7, 2014Inventors: Craig Boyle, William Greenlee, Samuel Chackalamannil, Claire Lankin
-
Publication number: 20140219954Abstract: The present invention relates to methods for making a stabilized powder formulation for inhalation comprising a macromolecule in lyophilized form, a crystalline carrier material, and magnesium stearate.Type: ApplicationFiled: March 17, 2014Publication date: August 7, 2014Inventor: Rudi Mueller-Walz
-
Publication number: 20140219963Abstract: Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.Type: ApplicationFiled: February 18, 2014Publication date: August 7, 2014Inventors: Stephen F. Badylak, Donald Freytes
-
Patent number: 8796201Abstract: Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.Type: GrantFiled: November 4, 2011Date of Patent: August 5, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Lu Shan, Michael Bethune, Chaitan Khosla, Jonathan Gass, Gail G. Pyle, Gary M. Gray, Indu Isaacs, Gregg Strohmeier
-
Patent number: 8778338Abstract: A combination enzyme product consisting of a glutamine specific endoprotease and a prolyl endopeptidase is provided. Both enzymes are active and stable in the stomach and can therefore be administered as lyophilized powders or simple capsules/tablets. A ratio of the two enzymes is used to maximize their synergy.Type: GrantFiled: March 14, 2008Date of Patent: July 15, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jonathan David Gass, Chaitan Khosla, Michael Bethune, Matthew John Siegel
-
Publication number: 20140186328Abstract: The present invention provides neuroprotective polyphenol compounds, which can be synthetic analogs of fisetin, baicalein or chlorogenic acid, that maintain neuroprotective, anti-inflammatory, glutathione promoting, and/or antioxidant properties. The neuroprotective polyphenol compounds are useful for promoting, enhancing and/or increasing neuron protection, growth and/or regeneration. The polyphenol compounds further find use for increasing and or maintaining intracellular glutathione (GSH) levels. The polyphenol compounds are also useful for treating, preventing, mitigating and/or delaying neurodegenerative conditions, including diabetes, Parkinson's disease, Huntington's disease, Alzheimer's disease, non-Alzheimer's dementias, multiple sclerosis, traumatic brain injury, spinal cord injury or ALS.Type: ApplicationFiled: February 5, 2014Publication date: July 3, 2014Applicant: Salk Institute for Biological StudiesInventors: David R. Schubert, Pamela A. Maher, Chandramouli Chiruta
-
Publication number: 20140178355Abstract: The invention provides compositions and methods for treating celiac sprue.Type: ApplicationFiled: August 10, 2012Publication date: June 26, 2014Inventors: Justin Siegel, David Baker, Sydney Rin Anna Gordon, Ingrid Swanson Pultz, Elizabeth Joy Stanley, Sarah Jane Wolf
-
Publication number: 20140161787Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.Type: ApplicationFiled: June 25, 2013Publication date: June 12, 2014Applicant: CUREMARK LLCInventor: Joan M. Fallon
-
Publication number: 20140148642Abstract: Apparatus and formulations for correcting and curing erectile dysfunction in men to create a natural erection without the use of primitive devices.Type: ApplicationFiled: January 10, 2011Publication date: May 29, 2014Inventor: Gene C. Benckini
-
Publication number: 20140147500Abstract: Pharmaceutical compositions comprising one or more digestive enzymes and one or more gastrointestinal modulators of acid are provided. The one or more digestive enzymes may be coated, e.g., with a lipid. Also disclosed are methods for their use and controlled delivery in treating individuals with neurological, behavioral, infectious, or genetic diseases or conditions susceptible to treatment with digestive enzymes.Type: ApplicationFiled: November 19, 2010Publication date: May 29, 2014Inventors: Joan M. Fallon, Matthew Heil, James F. Szigethy, James Fallon
-
Publication number: 20140134146Abstract: The present application discloses a fouling release cured paint coat comprising a polysiloxane-based binder matrix constituting at least 40% by dry weight of the coat, and one or more enzymes. The application further discloses a kit for preparing a fouling release coat, a coating composition comprising a polysiloxane-based binder system comprising one or more polysiloxane components modified with hydrophilic oligomer/polymer moieties, and one or more enzymes, and a coating composition comprising a polysiloxane-based binder system, 0.01-20% by dry weight of one or more hydrophilic-modified polysiloxane oils, and one or more enzymes.Type: ApplicationFiled: June 29, 2012Publication date: May 15, 2014Applicant: HEMPEL A/SInventors: Stefan Møller Olsen, Diego Meseguer Yebra
-
Publication number: 20140127307Abstract: The present invention relates to a small particle size composition comprising pancreatin containing digestive enzymes for use in patients in need, including pediatric, geriatric, and adult patients, particularly those patients with dysphagia or wherein enteral administration using such composition would be suitable. In addition, the invention is directed to the composition as particles, such as micropellets or microgranules having a high potency, high useable yield and at least 10%-90% of 400-800 ?m. Furthermore, the composition optionally has an improved enteric coating and concomitant improved stability and enzyme activity compared to conventional prepared enterically coated pancreatic enzyme particles.Type: ApplicationFiled: November 2, 2012Publication date: May 8, 2014Applicant: APTALIS PHARMA LIMITEDInventors: Gopi M. VENKATESH, Craig Kramer, Flavio Fabiani, Luigi Mapelli, Giovanni Ortenzi, Massimo Latino
-
Patent number: 8715648Abstract: Combinations of one or more anti-obesity drugs with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight comprised of a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA comprise about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics.Type: GrantFiled: August 13, 2012Date of Patent: May 6, 2014Assignee: Pivotal Therapeutics Inc.Inventors: George Jackowski, Rachelle Macsweeney, Nisar Shaikh, Jason Yantha, Valerie Schini-Kerth
-
Publication number: 20140120077Abstract: Methods for treating rhinitis in a subject are provided herein. The methods of the present invention comprise intranasal administration of a topical composition comprising a purified botulinum neurotoxin, a carrier and a viscosity modifier to one or more inner surfaces of the nose. The methods disclosed herein provide alternative methods for delivery of botulinum neurotoxin to the nasal anatomy for the treatment of rhinitis.Type: ApplicationFiled: October 28, 2013Publication date: May 1, 2014Applicant: Revance Therapeutics, Inc.Inventors: Curtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
-
Patent number: 8697066Abstract: Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a Clostridial neurotoxins, to treat various medical conditions, such as overactive bladder, benign prostatic hyperplasia, hyperhidrosis, for example.Type: GrantFiled: January 31, 2013Date of Patent: April 15, 2014Assignee: Allergan, Inc.Inventors: Franklin D. Gaylis, Andrew M. Blumenfeld
-
Publication number: 20140099297Abstract: The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer.Type: ApplicationFiled: September 13, 2013Publication date: April 10, 2014Applicant: Apeiron Biologics AGInventors: Manfred Schuster, Hans Loibner, Evelyne Janzek-Hawlat, Bernhard Peball, Stefan Stranner, Bettina Wagner, Robert Weik
-
Patent number: 8691213Abstract: The invention relates to the use of composition comprising free amino acids as a sole source of protein, a fatty acid source comprising long chain polyunsaturated fatty acids, a carbohydrate source comprising digestible and indigestible carbohydrates, and milk protein free Bifidobacteria for treating a person suffering from (a) colic, congestion, runny nose, wheezing, vomiting, diarrhea, bloody stools, mucus in stools, rash, eczema, gastroesophageal reflux, eosinophilic esophagitis or asthma; (b) cow's milk allergy and/or food protein intolerance; and/or (c) infections, wherein the indigestible carbohydrate is selected from a milk protein free source and the total composition is essentially free of intact proteins.Type: GrantFiled: July 5, 2007Date of Patent: April 8, 2014Assignee: SHS InternationalInventors: Jane Elizabeth Langford, Ian Sullivan, Catherine Teresa Deering, Sandra Helen Giffen
-
Patent number: 8685392Abstract: The invention relates to glutamine endopeptidase enzymes from Rothia spp. bacteria that are naturally associated with the oral cavity, formulations comprising the glutamine endopeptidase enzymes and the use thereof for the treatment, prevention of allergic reaction and diagnosis of gluten allergy related diseases such as Celiac Sprue, gluten allergy and/or dermatitis herpetiformis.Type: GrantFiled: October 7, 2010Date of Patent: April 1, 2014Assignee: Trustees of Boston UniversityInventors: Eva J. Helmerhorst, Frank G. Oppenheim
-
Publication number: 20140088502Abstract: An injector system for delivery of a pharmacological agent to biological tissue having a plurality of needles arranged in an array, a plurality of reservoirs configured to receive a pharmacological composition therein, the reservoirs being in fluid communication with a respective one of the plurality of needles, a pneumatic pressure source, a pneumatic drive system that is configured to induce a first discharge of the pharmacological composition out of the reservoirs and needles in a plurality of delivery modes, agent delivery volume control means for controlling volume of the pharmacological composition discharged from the needles, and a control system having actuation control means for controlling said pneumatic drive system. The control system is programmed to control the delivery modes.Type: ApplicationFiled: September 19, 2013Publication date: March 27, 2014Inventors: Robert G. Matheny, Bret Herscher, Michael Perry
-
Publication number: 20140086867Abstract: A method of inducing or promoting hair growth on the scalp of a subject, comprising the steps of (i) providing an ECM composition including at least one ECM material, (ii) administering inciting event means to a target location on the scalp of the subject to induce an inciting event at the target scalp location, and (iii) administering a therapeutically effective amount of said ECM composition to the target scalp location. In some embodiments, the ECM composition includes at least one additional biologically active agent.Type: ApplicationFiled: September 19, 2013Publication date: March 27, 2014Inventor: Robert G. Matheny
-
Publication number: 20140079671Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.Type: ApplicationFiled: September 19, 2011Publication date: March 20, 2014Applicants: TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA, TECNIFAR-INDÚSTRIA TÉCNICA FARMACÊUTICA, S.A.Inventors: Miguel Ângelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Ana Raquel Martins Barbosa
-
Patent number: 8673853Abstract: Provided herein are methods and devices for inducing the formation of functional replacement nonarticular cartilage tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues in a mammal.Type: GrantFiled: August 20, 2007Date of Patent: March 18, 2014Assignee: Stryker CorporationInventors: Slobodan Vukicevic, Vladimir Katic, Kuber T. Sampath
-
Patent number: 8673972Abstract: Methods of treating a head and neck cancer are disclosed.Type: GrantFiled: August 2, 2013Date of Patent: March 18, 2014Assignees: Foundation Medicine, Inc., UCL Business PLCInventors: Chris Hendrik Boshoff, Timothy Robert Fenton, Matthias Alexander Lechner, Philip James Stephens, Matthew J. Hawryluk, Roman Yelensky, Garrett Michael Frampton
-
Publication number: 20140065129Abstract: Methods for treating a subject for a parasympathetic bias mediated condition are provided. Aspects of the methods include modulating at least a portion of the subject's autonomic nervous system to increase the sympathetic/parasympathetic activity ratio in a manner effective to treat the subject for the parasympathetic bias mediated condition. In some instances, the subject is known to have parasympathetic bias. Also provided are devices that find use in practicing various embodiments of the methods.Type: ApplicationFiled: August 28, 2013Publication date: March 6, 2014Inventors: Anthony Joonkyoo Yun, Jeremy Thomas Yun, Eric Foster Yun
-
Patent number: 8663633Abstract: Methods for identifying modified proteases with modified substrate specificity or other properties are provided. The methods screen candidate and modified proteases by contacting them with a substrate, such as a serpin, an alpha macroglobulins or a p35 family protein or modified serpins and modified p35 family members or modified alpha macroglobulins, that, upon cleavage of the substrate, traps the protease by forming a stable complex. Also provided are modified proteases.Type: GrantFiled: July 2, 2012Date of Patent: March 4, 2014Assignees: Torrey Pines Institute for Molecular Studies, Catalyst Biosciences, Inc.Inventor: Edwin L. Madison
-
Publication number: 20140056870Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, which cleaves a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin Targeting Moiety that binds a Binding Site on the nociceptive sensory afferent, which can undergo endocytosis to be incorporated into an endosome; a protease cleavage site where the fusion protein is cleavable by a protease located between the non-cytotoxic protease and the galanin Targeting Moiety; a translocation domain that translocates the protease from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; a first spacer from 4 to 25 amino acids between the non-cytotoxic protease and protease cleavage site; and a second spacer comprising from 4 to 35 residues between the galanin Targeting Moiety and translocation domain. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.Type: ApplicationFiled: August 27, 2012Publication date: February 27, 2014Applicants: ALLERGAN, INC., SYNTAXIN LIMITEDInventors: Peter James, Keith Foster, John Chaddock, Kei Roger Aoki, Lance Steward, Joseph Francis
-
Patent number: 8658163Abstract: A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and a method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using the presence of chymotrypsin in the maternal GI tract as a biomarker to determine the likelihood of developing preeclampsia, a pregnancy induced hypertension, and eclampsia/toxemia is disclosed.Type: GrantFiled: March 13, 2008Date of Patent: February 25, 2014Assignee: Curemark LLCInventor: Joan M. Fallon
-
Patent number: 8652476Abstract: Methods and pharmaceutical compositions for treating severe ischemic events including cerebral infarction, cardiac infarction, or pulmonary embolism, comprising a thrombolytic intervention including thrombolytic agents and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are disclosed.Type: GrantFiled: January 26, 2012Date of Patent: February 18, 2014Assignee: Niigata UniversityInventors: Takayoshi Shimohata, Lawrence M. Kauvar
-
Publication number: 20140044680Abstract: A recombinant vector comprises simian adenovirus 28, simian adenovirus 27, simian adenovirus 32, simian adenovirus 33, and/or simian adenovirus 35 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses one or more simian adenovirus-28, -27, -32, -33, or -35 genes is also disclosed. Methods of using the vectors and cell lines are provided.Type: ApplicationFiled: August 16, 2013Publication date: February 13, 2014Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Soumitra Roy, James M. Wilson, Luk H. Vandenberghe
-
Publication number: 20140044700Abstract: The present invention provides methods of improving growth performance, improving the efficiency of feed utilization, increasing feed digestibility, and decreasing mortality of immature and developing animals receiving animal feed. Methods of producing a crude keratinise enzyme extract and animal feed supplements for achieving the same are also provided.Type: ApplicationFiled: October 23, 2013Publication date: February 13, 2014Inventor: Jason C.H. Shih
-
Publication number: 20140037614Abstract: The present invention provides a method for the prevention and/or reduction of peri- or postoperative complications following surgical intervention, such as complications following vascular surgery, especially peripheral vascular surgery, comprising administering a therapeutically effective amount of Annexin (A5) or a functional analogue or variant thereof to a patient in need of such treatment, Also provided is a pharmaceutical composition comprising a therapeutically effective amount of Annexin (A5) or a functional analogue or variant thereof for use in the prevention and/or reduction of peri- or postoperative complications following surgical intervention, such as complications following vascular surgery, especially peripheral vascular surgery.Type: ApplicationFiled: April 5, 2012Publication date: February 6, 2014Inventor: Knut Pettersson
-
Publication number: 20140030333Abstract: A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the maternal GI tract to determine the likelihood of developing preeclampsia, pregnancy induced hypertension, and eclampsia/toxemia is disclosed.Type: ApplicationFiled: September 26, 2013Publication date: January 30, 2014Applicant: CUREMARK, LLCInventor: Joan M. Fallon
-
Patent number: 8632771Abstract: Modifications of vitamin K-dependent polypeptides that lead to enhanced protein function on a weight or molar basis and/or increase of protein lifetime in the circulation are described. Both objectives are important for using vitamin K-dependent polypeptides for pro- and anti-coagulation therapies, as well as for other uses in the circulation.Type: GrantFiled: April 4, 2007Date of Patent: January 21, 2014Assignees: Regents of the University of Minnesota, The United States of America as represented by Department of Veterens AffairsInventors: Gary L. Nelsestuen, Ronald Bach, Matthew Stone, Stephen Barrett Harvey
-
Publication number: 20140010802Abstract: Systems, methods, and computer readable media for diagnosing or characterizing a genetic predisposition to develop cancer, including cancers of the BAP1 cancer syndrome, are provided. Nucleic acids comprising a germline nucleic acid sequence encoding the BRCA1 associated protein 1 (BAP1) are sequenced or probed to determine if the nucleic acid sequence includes alterations that predispose a subject to develop cancer.Type: ApplicationFiled: August 19, 2013Publication date: January 9, 2014Applicants: University of Hawaii, Office of Technology Transfer and Economic Development, Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center ("Fox Chase CInventors: Joseph R. Testa, Michele Carbone, Mitchell Cheung, Jianming Pei
-
Publication number: 20130344055Abstract: The present invention relates to a fusion protein composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and/or Gram-positive bacteria and at least two peptide stretches fused to the enzyme at the N- or C-terminus, wherein the peptide stretches are distinct and selected from the group of synthetic amphiphatic peptide, synthetic cationic peptide, synthetic polycationic peptide, synthetic hydrophobic peptide, or naturally occurring antimicrobial peptide, like sushi peptide and defensin. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, diagnostic means, cosmetic substance, a disinfectant or a food additive.Type: ApplicationFiled: December 23, 2011Publication date: December 26, 2013Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, LYSANDO AGInventors: Yves Briers, Rob Lavigne, Maarten Walmagh, Stefan Miller
-
Publication number: 20130315890Abstract: A method for selection and treatment of externally caused migraine headache, the method includes identifying a patient group having chronic migraine headache; determining the identified patient group, a specific patient with a post traumatic migraine headache; and administering to the selected patient by injection of a therapeutically effective amount of an invertebrate presynaptic neurotoxin in a pharmaceutically safe form to the selected patient's head or upper neck; administration preferably being on the sites of the trigeminal cervical system, enabling axonal transport of the neurotoxin from distal to central sites; and the administration preferably comprising extramuscular injection of the neurotoxin of suitable dilution (a) over the aponeurotic fascia to enable the neurotoxin to diffuse into distal sensory nerves, in order to concentrate the neurotoxin over the occipital-parietal-frontal head region, or (b) intra-orally, in a foramina of the sphenopalatine ganglion for enabling diffusion of the neurotoxType: ApplicationFiled: April 10, 2013Publication date: November 28, 2013Inventor: William J. Binder
-
Patent number: 8586319Abstract: The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life.Type: GrantFiled: June 12, 2008Date of Patent: November 19, 2013Assignee: Apeiron Biologics AGInventors: Manfred Schuster, Hans Loibner, Evelyne Janzek-Hawlat, Bernhard Peball, Stefan Stranner, Bettina Wagner, Robert Weik
-
Publication number: 20130295062Abstract: The present invention relates to methods and compositions for use in the treatment of neurological disorders, such as Alzheimer's disease and dementia. In one embodiment, the present invention provides a method of treatment of Alzheimer's disease in an individual by administering a composition overexpressing ACE to the individual. In another embodiment, the method of treatment comprises administering a composition comprising a therapeutically effective dosage of ACE.Type: ApplicationFiled: January 18, 2012Publication date: November 7, 2013Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Kenneth E. Bernstein, Maya Koronyo, Sebastien Fuchs, Yosef Koronyo
-
Publication number: 20130295078Abstract: A method of providing a pet with a benefit relating to effective assimilation of a lipid is described wherein the pet is administered, as a part of, or in addition to its regular diet, an edible composition that contains an ingredient that maintains, promotes or enhances the capacity of the pet to digest lipid efficiently. The invention extends to compositions for use in promoting lipid assimilation in pets, particularly senior or elderly pets. The compositions include pancreatic, liver and intestinal mucosa function-promoters. In embodiments, the liver function-promoter may be selected from taurine, emulsifiers, vitamins, minerals, glutathione and glutathione promoters.Type: ApplicationFiled: June 3, 2013Publication date: November 7, 2013Inventors: Gerardo Perez-Camargo, Avinash Patil, Carolyn Jean Cupp, Armand Malnoe
-
Publication number: 20130287830Abstract: Vehicles for delivery and release of pesticide compositions are provided. In one aspect, the delivery vehicle is a capsule configured to resist release of a pesticide composition before application of the capsule at a locus where pest control is desired. The capsule is further configured to degrade following application at the locus where pest control is desired to facilitate release of the pesticide composition. In one particular but non-limiting form, the capsule includes a shell wall including a relatively high Bloom strength gelatin material and a plasticizer material, and the pesticide composition includes a fumigant such as 1,3-dichloropropene. Further embodiments, forms, objects, features, advantages, aspects, and benefits shall become apparent from the description and drawings.Type: ApplicationFiled: April 25, 2013Publication date: October 31, 2013Applicant: Dow AgroSciences LLCInventors: Lorenzo Aulisa, John D. Busacca, Donald E. Williams,, III, Phillip J. Howard, Ashish Batra, Sara J. Linder
-
Publication number: 20130287756Abstract: Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found with krill oil and/or marine oil in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.Type: ApplicationFiled: June 11, 2013Publication date: October 31, 2013Inventors: John A. MINATELLI, W. Stephen Hill, Swati Sebastian Thomas, Lingan Rajendran, Rudi E. Moerck